Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.6500 +0.0740 (+12.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Dow Jumps Over 100 Points; Nvidia Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
Via ACCESSWIRE
Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Via ACCESSWIRE
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
Via ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
Via ACCESSWIRE
S&P 500 Edges Higher; American Woodmark Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; ScanSource Reports Weak Q4 Results
Via Benzinga
ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024
ENSC stock results show that Ensysce Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Via ACCESSWIRE
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Via ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Via ACCESSWIRE
ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024
ENSC stock results show that Ensysce Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Via ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Via ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Via ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Via ACCESSWIRE
FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today
Fisker stock is on the move Monday as FSR investors learn about the EV company securing an additional $150 million in funding. 
Via InvestorPlace
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Via ACCESSWIRE
ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023
ENSC stock results show that Ensysce Biosciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.